Alpha-1 抗胰蛋白酶缺乏症市场－全球产业规模、份额、趋势、机会和预测（按产品、给药途径、配销通路、地区和竞争细分，2020-2030 年）

2024 年全球 Alpha-1 抗胰蛋白酶缺乏症市场价值为 22.4 亿美元，预计到 2030 年将达到 35.3 亿美元，预测期内的复合年增长率为 7.82%。 Alpha-1 抗胰蛋白酶缺乏症（Alpha-1 抗胰蛋白酶缺乏症）是一种影响肺部和肝臟的罕见遗传性疾病。它是由 alpha-1 抗胰蛋白酶缺乏引起的，从而增加肺部和肝臟疾病的风险。虽然 Alpha-1 抗胰蛋白酶缺乏症被认为是一种罕见疾病，但它对患者的生活品质和医疗保健系统的影响却很大。随着研究的进展和认识的提高，Alpha-1 抗胰蛋白酶缺乏症市场正在转变，既带来挑战也带来机会。 Alpha-1 抗胰蛋白酶是由肝臟产生的一种蛋白质，在保护肺部免受发炎期间释放的酵素造成的损害方面起着至关重要的作用。患有α-1抗胰蛋白酶缺乏症的个体，其基因突变会导致一种错误折迭的蛋白质的产生，这种蛋白质会在肝臟中积聚，而不是被释放到血液中。这种缺陷导致患者更容易患上肺部疾病，例如慢性阻塞性肺病 (COPD)，以及肝臟疾病，例如肝硬化。

由于 Alpha-1 抗胰蛋白酶缺乏症 (Alpha-1 Antitrypsin Deficiency Disease) 的罕见性，该疾病的市场规模相对较小。然而，该疾病正受到研究人员、製药公司和医疗保健提供者的关注。该市场由几家专注于诊断、治疗和疗法的关键参与者组成。这些公司专注于开发旨在解决潜在缺陷并控制相关併发症的疗法。生物技术、基因组学和个人化医疗的进步，使得针对 Alpha-1 抗胰蛋白酶缺乏症的疗法更具针对性、更有效的开发成为可能。这些创新有可能彻底改变治疗方法，从而改善患者的治疗效果并提高生活品质。政府措施和增加的研究资金在推动全球 Alpha-1 抗胰蛋白酶缺乏症市场成长方面发挥了关键作用。随着人们对 Alpha-1 抗胰蛋白酶缺乏症等罕见疾病的认识不断提高，各国政府和监管机构正在出台政策和项目，以支持此类疾病的研究、诊断和治疗发展。研究项目、临床试验和患者支持计划的资金吸引了製药公司和研究人员的关注，从而加速了该领域的进步。

关键市场驱动因素

患者人数不断增长

主要市场挑战

诊断不足及误诊

主要市场趋势

技术进步

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球 α-1 抗胰蛋白酶缺乏症市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 副产品（α-1蛋白酶抑制剂、支气管扩张剂、皮质类固醇、氧气疗法）
  • 依给药途径（注射、口服、吸入）
  • 按配销通路（医院药房、零售药房、网路药房）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按产品
  • 依给药途径
  • 按配销通路
  • 按地区

第六章：北美 α-1 抗胰蛋白酶缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测

第七章：欧洲 Alpha-1 抗胰蛋白酶缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测

第 8 章：亚太地区 α-1 抗胰蛋白酶缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测

第九章：南美洲α-1抗胰蛋白酶缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测

第 10 章：中东与非洲 Alpha-1 抗胰蛋白酶缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 近期发展
• 併购
• 产品发布

第 13 章：竞争格局

• Shire plc
• GlaxoSmithKline plc
• CSL Behring
• AstraZeneca Plc.
• Grifols SA
• Teva Pharmaceutical Industries
• Boehringer Ingelheim International GmbH
• Kamada Pharmaceuticals
• Pfizer Inc.
• Baxter International Inc.

第 14 章：策略建议

第15章调查会社について・免责事项

The global Alpha-1 Antitrypsin Deficiency Disease Market was valued at USD 2.24 billion in 2024 and is expected to reach USD 3.53 billion by 2030, growing at a CAGR of 7.82% during the forecast period. Alpha-1 Antitrypsin Deficiency (Alpha-1 Antitrypsin Deficiency Disease) is a rare genetic disorder that affects the lungs and liver. It is caused by a deficiency in the alpha-1 antitrypsin protein, which leads to a higher risk of developing lung and liver diseases. While Alpha-1 Antitrypsin Deficiency Disease is considered a rare disease, its impact on patients' quality of life and healthcare systems is significant. As research advances and awareness grows, the Alpha-1 Antitrypsin Deficiency Disease Market is undergoing transformations, offering both challenges and opportunities. Alpha-1 antitrypsin is a protein produced by the liver that plays a crucial role in protecting the lungs from damage caused by enzymes released during inflammation. In individuals with Alpha-1 Antitrypsin Deficiency Disease, a genetic mutation leads to the production of a misfolded protein that accumulates in the liver rather than being released into the bloodstream. This deficiency results in a higher susceptibility to lung diseases like chronic obstructive pulmonary disease (COPD) and liver diseases like cirrhosis.

The Alpha-1 Antitrypsin Deficiency Disease market is relatively small due to the rare nature of the disease. However, it is gaining attention from researchers, pharmaceutical companies, and healthcare providers. The market is characterized by a few key players specializing in diagnostics, treatments, and therapies. These companies focus on developing therapies that aim to address the underlying deficiency and manage associated complications. Advancements in biotechnology, genomics, and personalized medicine have enabled the development of more targeted and effective therapies for Alpha-1 Antitrypsin Deficiency Disease. These innovations have the potential to revolutionize treatment approaches, leading to better patient outcomes and improved quality of life. Government initiatives and increased research funding have played a pivotal role in driving the growth of the global Alpha-1 Antitrypsin Deficiency Disease market. As awareness about rare diseases like Alpha-1 Antitrypsin Deficiency Disease increases, governments and regulatory bodies are introducing policies and programs to support research, diagnosis, and treatment development for such conditions. Funding for research projects, clinical trials, and patient support programs have attracted the attention of pharmaceutical companies and researchers, leading to accelerated advancements in the field.

Key Market Drivers

Growing Patient Population

Alpha-1 Antitrypsin Deficiency (AATD) is a rare but serious genetic disorder that impairs lung and liver function, primarily due to insufficient levels of the alpha-1 antitrypsin protein. Though historically underdiagnosed, awareness surrounding AATD is steadily increasing. According to the Alpha-1 Foundation, it is estimated that 1 in 2,500 individuals in the United States may have the condition, but only a fraction have been properly diagnosed. This growing recognition is leading to a larger identified patient pool, highlighting the urgent need for improved diagnostic infrastructure and targeted therapies to manage and treat the condition effectively.

Misdiagnosis remains a significant hurdle in the clinical journey of many AATD patients. Because symptoms such as shortness of breath and wheezing overlap with more common conditions like asthma or chronic obstructive pulmonary disease (COPD), proper diagnosis is often delayed. However, with the rollout of improved diagnostic tools and broader genetic testing programs, correct identification is becoming more feasible. A 2023 study indicated that over 60% of newly confirmed AATD cases were initially misdiagnosed, underscoring the critical importance of awareness campaigns and early screening initiatives in catching the disease sooner and enabling timely treatment interventions.

As the pool of diagnosed patients expands, so does the interest from pharmaceutical companies and researchers to develop targeted treatments. Enzyme replacement therapies (ERTs), which replenish the deficient alpha-1 antitrypsin protein, have become a cornerstone in managing AATD. These therapies help reduce lung inflammation and preserve respiratory function. At the same time, advancements in gene therapy and RNA-based treatments are providing hope for long-term or even curative solutions. The clinical pipeline is expanding rapidly, with a number of therapies in various stages of development, targeting both symptomatic relief and genetic correction.

The availability of multiple therapeutic options is not only enhancing patient care but also creating new opportunities in the healthcare market. This is especially true as physicians are becoming more equipped to tailor treatments to the severity and progression of the disease. Increasing participation in patient registries and real-world evidence collection are further contributing to a deeper understanding of AATD and enabling personalized medicine approaches. As more individuals are diagnosed and gain access to effective care, the growing patient population will continue to be a central driver in the advancement of the Alpha-1 Antitrypsin Deficiency Disease treatment landscape.

Key Market Challenges

Under diagnosis and Misdiagnosis

One of the most pressing challenges in the Alpha-1 Antitrypsin Deficiency (AATD) market is the high rate of underdiagnosis. Due to the rarity of the condition and low awareness among both patients and primary care providers, AATD often goes undetected for years. Many individuals remain asymptomatic until the disease has significantly progressed, making early intervention difficult. Even when symptoms appear such as shortness of breath or recurrent respiratory infections-they are frequently attributed to more common conditions like asthma or chronic obstructive pulmonary disease (COPD). This diagnostic delay not only worsens patient outcomes but also limits the window of opportunity for implementing effective treatments and managing disease progression proactively.

Misdiagnosis compounds the challenge, as individuals with AATD are often treated incorrectly for unrelated respiratory or liver conditions. These inappropriate treatments can lead to ineffective care, increased healthcare costs, and a delay in addressing the root genetic cause of the symptoms. For example, corticosteroids may be prescribed under the assumption of asthma, when in fact, AATD-related lung damage requires enzyme replacement or targeted therapy. Moreover, many clinicians lack familiarity with the specific diagnostic tests needed such as serum AAT levels and genetic testing-leading to oversight in patient evaluation. This systemic issue highlights the need for increased physician education, standardized screening protocols, and public awareness campaigns to ensure timely, accurate diagnosis and improve long-term patient care.

Key Market Trends

Technological Advancements

Technological strides in genetic screening have enabled early detection of Alpha-1 Antitrypsin Deficiency Disease. Genetic tests can identify specific mutations associated with the deficiency, allowing healthcare providers to diagnose individuals even before symptoms manifest. This proactive approach empowers patients to make informed decisions about their health and lifestyle, potentially mitigating the severity of complications. Further, the advent of precision medicine, which tailors treatment plans based on an individual's genetic makeup, is revolutionizing Alpha-1 Antitrypsin Deficiency Disease management. With insights gleaned from genetic testing, medical professionals can design personalized interventions, optimizing treatment efficacy and minimizing adverse effects. The emergence of gene therapy and gene editing technologies is creating exciting avenues for treating genetic disorders like Alpha-1 Antitrypsin Deficiency Disease. Researchers are exploring ways to replace or correct the mutated gene responsible for Alpha-1 Antitrypsin Deficiency Disease, potentially restoring normal protein production. These innovative approaches hold the promise of not just managing the symptoms but addressing the root cause of the condition. Telemedicine has become an essential tool in managing chronic diseases. Patients with Alpha-1 Antitrypsin Deficiency Disease can now access remote consultations with specialists, receive real-time guidance, and monitor their health using wearable devices. This facilitates regular check-ins and timely interventions, ultimately enhancing the overall quality of care. As the technological landscape continues to evolve, the prospects for individuals with Alpha-1 Antitrypsin Deficiency are looking increasingly optimistic. Innovative therapies, precise diagnostics, and personalized treatment plans are reshaping the Alpha-1 Antitrypsin Deficiency Disease landscape, offering renewed hope to patients and their families. However, challenges such as ethical considerations, accessibility, and cost-effectiveness must also be addressed to ensure that the benefits of these technological advancements are equitably distributed. The application of big data analytics and artificial intelligence (AI) in medical research has expedited the identification of potential drug candidates. AI algorithms can analyze massive datasets to pinpoint molecules that could modulate AAT production or function, expediting the drug discovery process.

Key Market Players

• Shire plc
• GlaxoSmithKline plc
• CSL Behring
• AstraZeneca Plc.
• Grifols S.A.
• Teva Pharmaceutical Industries
• Boehringer Ingelheim International GmbH
• Kamada Pharmaceuticals
• Pfizer Inc.
• Baxter International Inc.

Report Scope:

In this report, the Global Alpha-1 Antitrypsin Deficiency Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Alpha-1 Antitrypsin Deficiency Disease Market, By Product:

• Alpha-1 Proteinase Inhibitor
• Bronchodilato
• Corticosteroid
• Oxygen Therapy

Alpha-1 Antitrypsin Deficiency Disease Market, By Route Of Administration:

• Injection
• Oral
• Inhalation

Alpha-1 Antitrypsin Deficiency Disease Market, By Distribution Channel:

• Hospitals Pharmacy
• Retail Pharmacies
• Online Pharmacies

Alpha-1 Antitrypsin Deficiency Disease Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Alpha-1 Antitrypsin Deficiency Disease Market.

Available Customizations:

Global Alpha-1 Antitrypsin Deficiency Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Alpha-1 Proteinase Inhibitor, Bronchodilators, Corticosteroids, Oxygen Therapy)
  • 5.2.2. By Route Of Administration (Injection, Oral, Inhalation)
  • 5.2.3. By Distribution Channel (Hospitals Pharmacy, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map
  • 5.3.1. By Product
  • 5.3.2. By Route of Administration
  • 5.3.3. By Distribution Channel
  • 5.3.4. By Region

6. North America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
    • 6.2.4.1. United States Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.1.1. Market Size & Forecast
        • 6.2.4.1.1.1. By Value
      • 6.2.4.1.2. Market Share & Forecast
        • 6.2.4.1.2.1. By Product
        • 6.2.4.1.2.2. By Route of Administration
        • 6.2.4.1.2.3. By Distribution Channel
    • 6.2.4.2. Canada Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.2.1. Market Size & Forecast
        • 6.2.4.2.1.1. By Value
      • 6.2.4.2.2. Market Share & Forecast
        • 6.2.4.2.2.1. By Product
        • 6.2.4.2.2.2. By Route of Administration
        • 6.2.4.2.2.3. By Distribution Channel
    • 6.2.4.3. Mexico Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 6.2.4.3.1. Market Size & Forecast
        • 6.2.4.3.1.1. By Value
      • 6.2.4.3.2. Market Share & Forecast
        • 6.2.4.3.2.1. By Product
        • 6.2.4.3.2.2. By Route of Administration
        • 6.2.4.3.2.3. By Distribution Channel

7. Europe Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
    • 7.2.4.1. France Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.1.1. Market Size & Forecast
        • 7.2.4.1.1.1. By Value
      • 7.2.4.1.2. Market Share & Forecast
        • 7.2.4.1.2.1. By Product
        • 7.2.4.1.2.2. By Route of Administration
        • 7.2.4.1.2.3. By Distribution Channel
    • 7.2.4.2. Germany Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.2.1. Market Size & Forecast
        • 7.2.4.2.1.1. By Value
      • 7.2.4.2.2. Market Share & Forecast
        • 7.2.4.2.2.1. By Product
        • 7.2.4.2.2.2. By Route of Administration
        • 7.2.4.2.2.3. By Distribution Channel
    • 7.2.4.3. United Kingdom Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.3.1. Market Size & Forecast
        • 7.2.4.3.1.1. By Value
      • 7.2.4.3.2. Market Share & Forecast
        • 7.2.4.3.2.1. By Product
        • 7.2.4.3.2.2. By Route of Administration
        • 7.2.4.3.2.3. By Distribution Channel
    • 7.2.4.4. Italy Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.4.1. Market Size & Forecast
        • 7.2.4.4.1.1. By Value
      • 7.2.4.4.2. Market Share & Forecast
        • 7.2.4.4.2.1. By Product
        • 7.2.4.4.2.2. By Route of Administration
        • 7.2.4.4.2.3. By Distribution Channel
    • 7.2.4.5. Spain Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 7.2.4.5.1. Market Size & Forecast
        • 7.2.4.5.1.1. By Value
      • 7.2.4.5.2. Market Share & Forecast
        • 7.2.4.5.2.1. By Product
        • 7.2.4.5.2.2. By Route of Administration
        • 7.2.4.5.2.3. By Distribution Channel

8. Asia Pacific Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
    • 8.2.4.1. China Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.1.1. Market Size & Forecast
        • 8.2.4.1.1.1. By Value
      • 8.2.4.1.2. Market Share & Forecast
        • 8.2.4.1.2.1. By Product
        • 8.2.4.1.2.2. By Route of Administration
        • 8.2.4.1.2.3. By Distribution Channel
    • 8.2.4.2. India Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.2.1. Market Size & Forecast
        • 8.2.4.2.1.1. By Value
      • 8.2.4.2.2. Market Share & Forecast
        • 8.2.4.2.2.1. By Product
        • 8.2.4.2.2.2. By Route of Administration
        • 8.2.4.2.2.3. By Distribution Channel
    • 8.2.4.3. South Korea Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.3.1. Market Size & Forecast
        • 8.2.4.3.1.1. By Value
      • 8.2.4.3.2. Market Share & Forecast
        • 8.2.4.3.2.1. By Product
        • 8.2.4.3.2.2. By Route of Administration
        • 8.2.4.3.2.3. By Distribution Channel
    • 8.2.4.4. Japan Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.4.1. Market Size & Forecast
        • 8.2.4.4.1.1. By Value
      • 8.2.4.4.2. Market Share & Forecast
        • 8.2.4.4.2.1. By Product
        • 8.2.4.4.2.2. By Route of Administration
        • 8.2.4.4.2.3. By Distribution Channel
    • 8.2.4.5. Australia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 8.2.4.5.1. Market Size & Forecast
        • 8.2.4.5.1.1. By Value
      • 8.2.4.5.2. Market Share & Forecast
        • 8.2.4.5.2.1. By Product
        • 8.2.4.5.2.2. By Route of Administration
        • 8.2.4.5.2.3. By Distribution Channel

9. South America Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
    • 9.2.4.1. Brazil Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.1.1. Market Size & Forecast
        • 9.2.4.1.1.1. By Value
      • 9.2.4.1.2. Market Share & Forecast
        • 9.2.4.1.2.1. By Product
        • 9.2.4.1.2.2. By Route of Administration
        • 9.2.4.1.2.3. By Distribution Channel
    • 9.2.4.2. Argentina Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.2.1. Market Size & Forecast
        • 9.2.4.2.1.1. By Value
      • 9.2.4.2.2. Market Share & Forecast
        • 9.2.4.2.2.1. By Product
        • 9.2.4.2.2.2. By Route of Administration
        • 9.2.4.2.2.3. By Distribution Channel
    • 9.2.4.3. Colombia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 9.2.4.3.1. Market Size & Forecast
        • 9.2.4.3.1.1. By Value
      • 9.2.4.3.2. Market Share & Forecast
        • 9.2.4.3.2.1. By Product
        • 9.2.4.3.2.2. By Route of Administration
        • 9.2.4.3.2.3. By Distribution Channel

10. Middle East & Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
    • 10.2.4.1. South Africa Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.1.1. Market Size & Forecast
        • 10.2.4.1.1.1. By Value
      • 10.2.4.1.2. Market Share & Forecast
        • 10.2.4.1.2.1. By Product
        • 10.2.4.1.2.2. By Route of Administration
        • 10.2.4.1.2.3. By Distribution Channel
    • 10.2.4.2. Saudi Arabia Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.2.1. Market Size & Forecast
        • 10.2.4.2.1.1. By Value
      • 10.2.4.2.2. Market Share & Forecast
        • 10.2.4.2.2.1. By Product
        • 10.2.4.2.2.2. By Route of Administration
        • 10.2.4.2.2.3. By Distribution Channel
    • 10.2.4.3. UAE Alpha-1 Antitrypsin Deficiency Disease Market Outlook
      • 10.2.4.3.1. Market Size & Forecast
        • 10.2.4.3.1.1. By Value
      • 10.2.4.3.2. Market Share & Forecast
        • 10.2.4.3.2.1. By Product
        • 10.2.4.3.2.2. By Route of Administration
        • 10.2.4.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Shire plc
• 13.2. GlaxoSmithKline plc
• 13.3. CSL Behring
• 13.4. AstraZeneca Plc.
• 13.5. Grifols S.A.
• 13.6. Teva Pharmaceutical Industries
• 13.7. Boehringer Ingelheim International GmbH
• 13.8. Kamada Pharmaceuticals
• 13.9. Pfizer Inc.
• 13.10. Baxter International Inc.

14. Strategic Recommendations

15. About us & Disclaimer